Alejandro Alvarez is a Nephrology physician affiliated with Duke Medical Center. OpenAlex indexes 25 publications with 701 citations (h-index 6); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
201 Dunn Rd
Florissant, MO 630317928
Telephone
314-830-3841Provider last certified this registry record 13 Aug 2025.
Clinical trials
- Sacituzumab govitEcan in THYroid Cancers
Sponsor: Grupo Espanol de Tumores Neuroendocrinos
- Pivotal Study of the Vienna Transcatheter Self Expandable Aortic Valve SE System
Sponsor: P+F Products + Features GmbH
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
26 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Bard Peripheral Vascular, Inc.Program year20259 payments
- Becton, Dickinson and CompanyProgram year20253 payments
- VentureMed Group, Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
48%Corticosteroid26%Prednisone100%Part D<11 patientsOsmotic Laxative22%Lactulose100%Part D≥11 patientsDermatology
30%Corticosteroid30%Methylprednisolone100%Part D≥12 patientsBlood & clotting
22%Factor Xa inhibitor22%Eliquis100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Outcomes among patients bridged to heart transplant with microaxial flow versus durable left ventricular assist device support
Journal of Thoracic and Cardiovascular Surgery
2025 - Understanding consumer food choices & promotion of healthy and sustainable Mediterranean diet and lifestyle in children and adolescents through behavioural change actions: the DELICIOUS project
International Journal of Food Sciences and Nutrition
2024 - Targeting the Mevalonate Pathway Suppresses VHL-Deficient CC-RCC through an HIF-Dependent Mechanism
Molecular Cancer Therapeutics
2018
Similar KOLs
Other experts from the same institution or the same specialty.
James Abbruzzese, MD
Duke Medical Center
David Durack, MD
Duke Medical Center
Leonard Prosnitz, MD
Duke Medical Center
Scott Cousins, MD
Duke Medical Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”